Synthesis of Hepatitis B Compounds via Segmented Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing synthetic approach for compounds of formula (I) is inefficient due to low yield, unavailability of starting materials, need for column purification, racemic intermediates, robustness issues with Swern oxidation, and poor conversion and purity in the final step, making it unsuitable for commercial production.
Innovation Solution
A novel process involving the formation of isocyanate, urea, cyclization, protection, reduction, hydrolysis, de-protection, Biginelli-like reaction, and recrystallization steps to synthesize compounds of formula (I) with improved yield and purity, eliminating the need for chiral separation and reducing impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the existing synthetic approach (WO 2015/132276) is used, then the compound can be synthesized, but the overall yield is very low (0.2-0.4%)
Solution Approach 1:
The synthesis is divided into distinct modular steps with intermediate isolation and purification at strategic points. The process segments the multi-step synthesis into manageable stages (Steps A-D), each optimized for high yield and purity, allowing for better control and reduced cumulative loss.
Solution Approach 2:
The patent optimizes reaction parameters including temperature, solvent systems, reagent ratios, and reaction times for each step. Specific parameters are tuned to maximize yield at each stage, such as controlling the cyclization temperature and using specific solvent combinations to enhance reaction efficiency and product isolation.
2Manufacturing precision
If column purification is performed for four intermediates, then purity is improved, but the device complexity and time consumption increase significantly
Solution Approach 1:
The patent extracts and removes unnecessary purification steps from the synthesis pathway. By carefully designing the reaction sequence and selecting appropriate solvents and reagents, the process achieves sufficient purity through simpler filtration and crystallization steps rather than requiring four separate column purifications.
Solution Approach 2:
The patent replaces expensive, time-consuming column chromatography with simpler, more economical purification methods such as filtration and crystallization. These alternative methods are less complex, faster, and more suitable for scale-up while maintaining adequate purity levels for pharmaceutical manufacturing.
3Manufacturing precision
If chiral HPLC or chiral SFC is used for intermediate purification, then enantiomeric purity is improved, but the device complexity and cost increase
Solution Approach 1:
The patent performs preliminary chiral resolution at an early stage in the synthesis by resolving a racemic intermediate. This preliminary chiral separation allows subsequent steps to proceed with enantiomerically pure materials, eliminating the need for expensive chiral HPLC or SFC equipment later in the process.
Solution Approach 2:
Instead of using complex chiral chromatography to separate enantiomers, the patent inverts the approach by using diastereomeric salt formation followed by fractional crystallization. This classical method achieves chiral separation through differences in solubility rather than chromatographic retention, avoiding the need for specialized chiral equipment.
4Reliability
If Swern oxidation is used, then the oxidation reaction proceeds, but it is not robust for large scale and has potential racemization issues
Solution Approach 1:
The patent replaces Swern oxidation with a more robust alternative oxidation method that is better suited for large-scale manufacturing. The new method avoids the limitations of Swern oxidation (low temperature requirements, sensitivity to moisture, racemization risks) while achieving the desired oxidation transformation with improved reliability and scalability.
5Ease of manufacture
If the final step uses the sticky semi-solid TFA salt, then the reaction can proceed, but conversion is poor and impurities increase requiring HPLC purification
Solution Approach 1:
The patent optimizes the final step by changing physical parameters such as solvent selection, temperature control, and addition rates. These parameter adjustments improve conversion and reduce impurity formation, eliminating the need for HPLC purification in the final step.
Solution Approach 2:
The patent converts the problematic sticky semi-solid intermediate into a beneficial form by using it in situ without isolation or by transforming it into a more manageable form during the final reaction. This approach turns a manufacturing nuisance into an acceptable intermediate that proceeds efficiently to the final product with high purity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new process achieves higher yields and desired purity, addressing the inefficiencies of the previous method and enabling commercial-scale production of the compound, which is useful for treating hepatitis B infection.
Implementation Method 1
compounds of formula (I) is obtained from the reaction of the compound of formula (X) with the compound of formula (XVIII)
Data Source
Figure 1
AI summary
The present invention relates to a process for synthesizing a compound of formula (I), R1 is phenyl, which is unsubstituted or substituted with one, two or three substituents independently selected from halogen and C1-6alkyl; R2 is C1-6alkyl; R3 is -CxH2x-; x is 1, 2, 3, 6 or 7; or pharmaceutically acceptable salt or diastereomer thereof, which is useful for prophylaxis and treatment of a viral disease in a patient relating to hepatitis B infection or a disease caused by hepatitis B infection.